After processing raw data, we performed three different DEAs, in which we compared the expression data of: (a) patient samples and the samples of healthy controls, (b) samples from higher‐ and lower‐risk MDS patients, and (c) samples of patients with an SF3B1 mutation and those with no mutation detected. Here, SF3B1 is linked to myelodysplastic syndrome.